Immunic, Inc. (NASDAQ:IMUX) Stock Has Average Price Target of $35.43

Immunic, Inc. (NASDAQ:IMUX) has received a consensus recommendation of “Buy” from the twelve analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, seven have given a buy recommendation and three have given a strong buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $35.43.

A number of equities analysts have recently issued reports on the stock. Wall Street Zen cut shares of Immunic from a “hold” rating to a “sell” rating in a research note on Saturday. LADENBURG THALM/SH SH upgraded shares of Immunic to a “strong-buy” rating in a research report on Wednesday, July 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunic in a research note on Wednesday, August 26th. Wedbush reissued an “outperform” rating and issued a $45.00 target price on shares of Immunic in a research note on Thursday, September 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of Immunic in a research report on Thursday, September 10th.

Institutional Investors Weigh In On Immunic

Several large investors have recently modified their holdings of the stock. Braidwell LP acquired a new stake in shares of Immunic during the second quarter worth $9,914,000. Avidity Partners Management LP increased its holdings in Immunic by 42.6% in the first quarter. Avidity Partners Management LP now owns 6,699,411 shares of the company’s stock valued at $7,436,000 after purchasing an additional 2,000,000 shares during the last quarter. CTC Alternative Strategies Ltd. bought a new stake in Immunic in the first quarter valued at about $27,000. Bank of America Corp DE increased its holdings in Immunic by 80,724.2% in the first quarter. Bank of America Corp DE now owns 143,867 shares of the company’s stock valued at $160,000 after purchasing an additional 143,689 shares during the last quarter. Finally, ADAR1 Capital Management LLC acquired a new position in Immunic in the first quarter valued at about $33,000. 51.82% of the stock is currently owned by institutional investors.

Immunic Stock Performance

IMUX opened at $6.89 on Friday. Immunic has a 1 year low of $5.06 and a 1 year high of $17.43. The stock’s 50 day simple moving average is $12.33 and its 200-day simple moving average is $12.73.

Immunic (NASDAQ:IMUX) last issued its earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.36. As a group, equities analysts expect that Immunic will post -3.71 earnings per share for the current year.

About Immunic

Immunic, Inc is a clinical-stage biotechnology company developing orally administered therapies for chronic inflammatory and autoimmune diseases. The company focuses on selectively modulating the immune system while seeking to avoid broad immunosuppression, with an emphasis on conditions affecting the central nervous system and gastrointestinal tract.

Immunic’s lead investigational product is vidofludimus calcium, formerly known as IMU-838. The oral, selective dihydroorotate dehydrogenase inhibitor is being studied in clinical trials for multiple sclerosis, including relapsing and progressive forms of the disease.